« Thou Shalt Not 'Ster, Part II |
| Hollywood Breaks Losing Streak? »
July 11, 2005
Brazil and Abbott Labs Reach Deal
The BBC reports that Abbott has signed a deal with the Brazilian government for its anti-AIDS drug Kalestra. The deal involves gradual price reductions over six years and access to Kalestra's successor. Brazil projects savings of USD 250 million over that time period and anticipates continuing to offer free anti-retroviral drugs to all needy patients in the country.
As I noted back in June, drug patents push uncomfortably into areas where IP rights may come into conflict with governmental initiatives and even fundamental human rights. Anti-HIV campaigners had argued that Brazil's situation qualified under WTO rules for patent suspension. For now that will remain an academic debate; however, Brazil is far from the only country with a growing AIDS epidemic and other similar situations are likely to arise in the near future.
+ TrackBacks (0) | Category: IP Markets and Monopolies
- RELATED ENTRIES
- CBS to HBO: Wait for Us!
- Sometime Next Year, HBO Will Become Netflix
- OpenMedia vs the TPP
- CopyrightX 2015 (online course) Now Open
- College Students vs Rising Textbook Prices
- "Amazon is crowdsourcing their slush pile"
- Rule 84 and Patent Trolls
- Sports Continue to Tiptoe Away from Cable Monopolies